As of September 15 at 09:59, Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) fell 0.90%, with a latest price of HKD 15.450.
As of September 15 at 09:55, CSOP FTSE China A50 ETF (02822.HK) fell 0.52%, with a latest price of HKD 15.160.
On 14 September 2026, HING YIP HLDGS (00132.HK) announced that Guangdong Lujin Finance Leasing Co., Ltd., a subsidiary of the Company, as lessor, entered into a finance lease with Sheyang County Sewage Treatment Co., Ltd., acquiring ownership of the assets for RMB 20,000,000 (equivalent to approximately HKD 23,380,000) and leasing them back for three years, which constitutes a discloseable transaction under the Listing Rules.
Weekly Hong Kong ETFs Average Return Statistics (By Fund Manager) (Second Week of September 2026)
Weekly Hong Kong ETFs Return Statistics (Second Week of September 2026)
On September 14, 2026, the main theme of the HK shares ETFs market switched to biotech. ChinaAMC Hang Seng Hong Kong Biotech Index ETF rose 4.07% to lead, followed by CSOP Hang Seng Biotech ETF and Global X China Biotech ETF, with biotech ETFs sweeping the top three gainers; dividend, EV and new-economy themes posted modest gains. On the downside, Phillip HK Newly Listed Equities Index ETF plunged 6.87% to top the losers, while Korea and semiconductor themes fell sharply, with Xtrackers MSCI Korea UCITS ETF, CSOP KOSPI 200 ETF and E Fund (HK) Solactive Asia Semiconductor Select Index ETF all dropping more than 3%. Southbound Stock Connect ETFs moved in the same direction as the wider market, with biotech leading the gains and Hong Kong-Korea tech and iShares Core MSCI China Index ETF leading the declines.
As of 15:56, September 14, 2026, CSOP NASDAQ-100 Index Daily (-2x) Inverse Product (07568.HK) rose 2.12% to HK$2.414.
As of 15:53 on September 14, ChinaAMC Asia High Dividend ETF (03145.HK) fell 2.05% to HKD 14.350, with a turnover of approximately HKD 45.3154 million and assets under management of approximately HKD 1.403 billion.
As of 15:50, September 14, 2026, Csop Nikkei 225 Daily (-2x) Inverse Product (07515.HK) climbed 2.56% to HK$15.250.
As of 15:48 on September 14, iShares Core MSCI Taiwan Index ETF (03074.HK) fell 1.55% to HKD 484.000, with assets under management of approximately HKD 910 million and a turnover of approximately HKD 2.406 million.
As of 15:41 on September 14, Global X China Semiconductor ETF (03191.HK) fell 3.37% to HKD 78.660, with a premium of 1.26%, a turnover of approximately HKD 13.5769 million, and assets under management of approximately HKD 3.521 billion.
As of 15:36 on September 14, Phillip HK Newly Listed Equities Index ETF (02835.HK) fell 7.21% to HKD 8.305, with a turnover of approximately HKD 101,600 and assets under management of approximately HKD 60.94 million.
On September 14, 2026, pharmaceutical & biotechnology and innovative drugs themes strengthened collectively in the Shanghai-Shenzhen Stock Connect ETFs market and led the gainers; meanwhile, previously active sectors including military, communication and aerospace pulled back notably.
as of 15:00 on September 14, 2026, the CSI Battery Thematic Index (931719) rose 1.30%, with the China Merchants CSI Battery Thematic ETF (561910) last quoted at RMB 0.67.In terms of fund flows, the China Merchants CSI Battery Thematic ETF recorded a latest net fund outflow of RMB 6.6034 million. Over a longer horizon, it saw net fund inflows on 3 of the past 5 trading days, totaling RMB 16.5356 million in "fund attraction", with an average daily net inflow of RMB 3.3071 million. Data shows that leveraged funds continue to build positions. The China Merchants CSI Battery Thematic ETF recorded net margin buying of RMB 2.3827 million on the previous trading day, with a latest margin balance of RMB 50.5359 million.
As of 15:26 on September 14, E Fund (HK) Solactive Biopharma Select Index ETF (03186.HK) rose 2.24% to HKD 14.600, with a turnover of approximately HKD 23,100 and assets under management of approximately HKD 24.28 million.
As of 15:17 on September 14, ChinaAMC Hang Seng Hong Kong Biotech Index ETF (03069.HK) rose 3.94% to HKD 15.570, with a turnover of approximately HKD 69.2478 million and assets under management of approximately HKD 2.378 billion.
